BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ARQ-234 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ARQ-234\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07453602-1289@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:ARQ-234: Phase 1 readout est. (NCT07453602)
DESCRIPTION:ARQ-234\, phase 1\, Atopic Dermatitis.\nStudy: Ph 1a/1b Single 
 Ascending Dose and Multiple Ascending Dose Study of ARQ-234\nEstimated pri
 mary completion: April 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/arq-234#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07453602
URL:https://assetmemo.bio/drug/arq-234#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
